What Are Treatment Options After Progression in PDL-1-Positive Metastatic Lung Adenocarcinoma after Chemo/IO?

Oncology (Williston Park). 2019 Aug 23;33(8):683728.
No abstract available

Publication types

  • Case Reports

MeSH terms

  • Adenocarcinoma of Lung / metabolism
  • Adenocarcinoma of Lung / pathology
  • Adenocarcinoma of Lung / therapy*
  • Antibodies, Monoclonal, Humanized / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • B7-H1 Antigen / antagonists & inhibitors*
  • B7-H1 Antigen / metabolism
  • Bone Neoplasms / drug therapy*
  • Bone Neoplasms / metabolism
  • Bone Neoplasms / secondary
  • Brain Neoplasms / drug therapy*
  • Brain Neoplasms / metabolism
  • Brain Neoplasms / secondary
  • Carboplatin / administration & dosage
  • Docetaxel / administration & dosage
  • Female
  • Humans
  • Lung Neoplasms / metabolism
  • Lung Neoplasms / pathology
  • Lung Neoplasms / therapy*
  • Lymphatic Metastasis
  • Middle Aged
  • Pemetrexed / administration & dosage
  • Prognosis

Substances

  • Antibodies, Monoclonal, Humanized
  • B7-H1 Antigen
  • CD274 protein, human
  • Pemetrexed
  • Docetaxel
  • Carboplatin
  • pembrolizumab